Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer
Study sponsor: CytomX Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-06-02Actual
Enrollment · participants125Actual
Source updated2024-01-23Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.